Cannabis Europa is proud to announce MPX International Corporation as the Biomedical partner for our New York conference on November 7th at the Metropolitan club.
MPX International Corporation is a Canadian vertically integrated, global cannabis company focused on developing and operating assets with an emphasis on cultivating, manufacturing and distributing its products.
With an established presence in six markets including Canada, Australia, Malta, South Africa, Switzerland and the United Kingdom, MPX International Corporation proposes a diversified asset base that targets medical, health, wellness and recreational channels including their brands HolyWeed and Salus BioPharma. Having recently acquired a 20% stake in KAAJENGA Cannabis, a private social network designed to share information about the cannabis industry, MPX International Corporation secured the exclusive rights to a video learning and engagement platform called Cannabis Kiosk Solution. This investment provides MPX International Corporation with an exclusive, worldwide royalty-free licence to develop the Cannabis Kiosk Solution, which will act as a video-based learning platform aimed at giving patients access to a secure, compliant and controlled learning environment.
As we build our product suite, our international operations and our production capacity, building a compliant learning network to reach global markets made a lot of sense to us and positioned us strategically for patient acquisition through learning (…) The Unique Cannabis Kiosk solution (CKS) model is best-in-class and will help us scale globally. People from all over the world have questions and we wanted to provide answers and this investment ensures we lead the way. – W. Scott Boyes, Chairman, President and CEO of MPX International Corporation
MPX International Corporation executives have been developing leading cannabis operations since 2015 in order to bring innovative and award-winning products to both consumer and medical industries. Through years of developing cultivation facilities, MPX International Corporation executives have managed to successfully create a variety of different formats, from highly-automated indoor grows to multi-hectare outdoor farms that can operate in both regulated medical markets and rapidly evolving consumer markets such as that in Europe.
The European cannabis market represents a tremendous opportunity that MPX International is strategically targeting for significant growth. We have created first mover advantages there that we anticipate will result in MPXI and its premium brands – such as HolyWeed and Salus BioPharma – gaining increasing brand awareness as markets across the continent continue to open up. As more countries across the globe – including those in Europe – move towards the legalization of cannabis, MPXI’s expertise and proven track record in navigating multi-jurisdictional regulations will help continue to drive our success. – W. Scott Boyes, Chairman, President and CEO of MPX International Corporation
Join us on November 7th at New York’s Metropolitan club to learn about the latest news concerning research, innovation and the production of medicinal cannabis in Europe from those who are at the forefront of this change.